June 23, 2026

STAT Breaks FDA-Lilly Retatrutide Compassionate-Use for Mystery 79-Year-Old, Elicio AMPLIFY-7P KRAS Vaccine Misses Phase 2 Primary, Hims & Hers Stock Above $30 on PCAC Catalyst, Medicare GLP-1 Bridge Launches July 1

STAT: FDA-Lilly retatrutide compassionate use for mystery 79-year-old; Elicio AMPLIFY-7P miss; Hims stock above $30 on PCAC; Medicare GLP-1 Bridge July 1.

4 stories · Covering regulatory, industry, clinical-trials

Editor's Note

Tuesday's defining story landed on STAT News at 5:00 AM ET: the FDA and Eli Lilly granted a single 79-year-old patient compassionate-use access to retatrutide on the application of an NIH senior clinician (Dr. Ranganath Muniyappa) citing refractory obesity plus obstructive sleep apnea plus pulmonary hypertension. Outside medical experts told STAT the diagnoses don't clearly meet the compassionate-use threshold (typically reserved for terminal illness), and the White House had to publicly deny that President Trump applied for early access. The story crystallizes the peptide-access-equity tension just as the Medicare GLP-1 Bridge prepares to launch July 1 for the broader Part D population at $50/month. On the industry side, Hims & Hers (HIMS) broke above $30 for the first time since April on FirstWave Fund analyst Jonah Lupton's $10-19B by-2030 peptide-revenue forecast tied to the July 23-24 PCAC meeting outcome (HIMS now +36% in June). On the clinical-trials side, Elicio Therapeutics' Phase 2 AMPLIFY-7P trial of the KRAS-targeting peptide cancer vaccine ELI-002 7P missed its primary disease-free survival endpoint in adjuvant pancreatic cancer, though post-hoc landmark analyses showed a 14% absolute DFS benefit during active treatment at both 3 and 6 months; Elicio is refining its Phase 3 strategy. The week's regulatory drumbeat continues toward Wednesday July 1 (Medicare GLP-1 Bridge live) and the July 23-24 PCAC meeting that will determine 503A compounding eligibility for BPC-157, KPV, TB-500, MOTS-C, Emideltide, Semax, and Epitalon.

Regulatory

STAT News (June 23): FDA and Eli Lilly Grant Mystery 79-Year-Old Patient Compassionate-Use Access to Retatrutide — NIH's Dr. Ranganath Muniyappa Applied, White House Denies Trump Application

STAT News broke June 23, 2026 that the FDA and Eli Lilly approved a single 79-year-old patient for compassionate-use access to retatrutide (Lilly's GIP/GLP-1/glucagon triple agonist still in Phase 3 development). Dr. Ranganath Muniyappa, a senior clinician at the National Institutes of Health, submitted the application in April citing diagnoses of refractory obesity, obstructive sleep apnea, and pulmonary hypertension. Outside medical experts told STAT the diagnoses don't clearly meet the compassionate-use threshold typically reserved for immediately life-threatening illness; Jamy Ard (chief science officer, Advocate Health) said 'compassionate use is usually reserved for terminal illness.' Compassionate use programs typically serve patients facing imminent death without alternatives, not refractory obesity even with severe comorbidities. The White House had to publicly deny that President Trump submitted the application. The patient's identity has not been confirmed. The episode crystallizes the peptide-access-equity tension at a moment when the broader US population continues to source retatrutide through gray-market research-chemical channels with no oversight.

#retatrutide #eli-lilly #compassionate-use #fda #nih #muniyappa #access-equity

Industry

Hims & Hers (HIMS) Stock Breaks Above $30 First Time Since April on PCAC July 23-24 Catalyst — FirstWave Fund Analyst Jonah Lupton Projects $10-19B Annual Peptide Revenue by 2030

Hims & Hers Health (NYSE: HIMS) broke above $30 on June 22, 2026 for the first time since April, finishing the month +36% — its best month since March — on rising investor confidence in the company's peptide platform ahead of the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) meeting. Leerink called the PCAC meeting a key catalyst, framing peptides as Hims' next major product category supporting growth beyond 2027. FirstWave Fund CEO Jonah Lupton projected Hims could generate $10-19 billion in annual peptide-related revenue by 2030 if it captures 4-5% of the combined GLP-1 and non-GLP-1 peptide markets. Hims acquired a California peptide manufacturing facility in 2025 and added in-house lab testing capabilities. CEO Andrew Dudum confirmed Oura Ring integration is 'coming soon,' signaling deeper wearable connectivity. The June 22-23 stock move reflects the broader market consensus that PCAC will reclassify the seven peptides under review (BPC-157, KPV, TB-500, MOTS-C, Emideltide, Semax, Epitalon) and open compounding-pharmacy supply channels.

#hims-hers #stock-breakout #pcac #peptide-compounding #telehealth #analyst-forecast

Clinical Trials

Elicio Therapeutics AMPLIFY-7P Phase 2 (June 15): ELI-002 7P KRAS Peptide Vaccine Misses Primary DFS Endpoint in Adjuvant Pancreatic Cancer, But Shows 14% Absolute DFS Benefit During Active Treatment — Phase 3 Strategy Refined

Elicio Therapeutics announced June 15, 2026 that the randomized Phase 2 AMPLIFY-7P study of ELI-002 7P (a 7-peptide formulation targeting the seven most common KRAS mutations, combined with the ELI-004 amphiphile-modified CpG oligonucleotide adjuvant) in patients with adjuvant mKRAS-driven pancreatic ductal adenocarcinoma did not meet its pre-specified primary disease-free survival (DFS) endpoint in the intent-to-treat population. Post-hoc landmark analyses, however, showed a consistent 14% absolute DFS benefit during active treatment at both 3 and 6 months, with treatment-arm separation persisting through 9 months — suggesting early clinical activity that waned over time. Elicio is refining its Phase 3 development strategy based on the data. The 7P formulation extends the 2-peptide ELI-002 2P AMPLIFY-201 program covered in this site's April 29 digest (Nature Medicine publication, durable T-cell responses, median RFS not reached vs 3.02 months in non-responders). KRAS mutations drive roughly 90% of pancreatic cancers and 50% of colorectal cancers, making the KRAS peptide vaccine class one of the highest-impact targets in solid-tumor oncology.

#elicio-therapeutics #eli-002-7p #amplify-7p #kras-peptide-vaccine #pancreatic-cancer #amphiphile-vaccine #phase-2-miss

Regulatory

Medicare GLP-1 Bridge Launches July 1, 2026 — 8 Days Out: $50/Month Copay for Wegovy Pill, Wegovy Injection, Zepbound KwikPen, and Foundayo for Eligible Part D Beneficiaries Through December 31, 2027

The Centers for Medicare and Medicaid Services' GLP-1 Bridge demonstration launches Wednesday July 1, 2026 — 8 days from this digest's publication — providing eligible Medicare Part D beneficiaries with $50/month access to Foundayo (orforglipron), Wegovy injection, Wegovy pill, and Zepbound KwikPen for chronic weight management. The program runs through December 31, 2027 as a short-term bridge to the broader BALANCE Model (launching January 2027 in Medicare Part D). Humana, the current administrator of the Limited Income Newly Eligible Transition (LI NET) program, serves as the single central processor for prior authorization, claims adjudication, and pharmacy payment. CMS published the prior authorization fax form and prescriber/pharmacy educational materials on June 3, 2026. Eligibility requires BMI ≥30 (or ≥27 with comorbidities) and Part D enrollment. The launch arrives the same week as the Hims & Hers stock breakout and the FDA retatrutide compassionate-use disclosure — a coincidence that sharpens the peptide-access-equity debate as the broader US population continues to navigate $1,000+/month branded GLP-1 list prices.

#medicare-glp-1-bridge #cms #july-1-launch #balance-model #humana #part-d #obesity-coverage